for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CORRECTED-BRIEF-AstraZeneca Says Calquence Approved In Japan For CLL

(Corrects spelling of AstraZeneca in headline)

Jan 25 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - CALQUENCE APPROVED IN JAPAN FOR CLL

* ASTRAZENECA - CALQUENCE APPROVED IN JAPAN FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA

* ASTRAZENECA - 88% OF PATIENTS ON CALQUENCE REMAINED FREE OF DISEASE PROGRESSION AFTER 12 MONTHS VERSUS. 68% FOR COMPARATORS

* ASTRAZENECA - JAPANESE PHASE I/II TRIAL BASED ON ELEVATE TN PHASE III TRIAL IS CURRENTLY UNDERWAY FOR TREATMENT OF 1ST-LINE CLL Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up